22 Aug, 2023: The UK’s national innovation agency, Innovate UK is injecting £13 Million into the biopharmaceutical manufacturing sector in the UK. This financial infusion is a component of the broader effort to bolster the country's domestic Life Sciences field.
The Innovate UK Transforming Medicine Manufacturing program has revealed its decision to provide funding for seventeen novel projects in the realm of advanced medicine production. The selected projects centre around areas such as nucleic acid medicines, intracellular drug delivery and the implementation of digitalisation and automation.
This financial commitment is indicative of the increased attention, the UK government is directing towards the field of life sciences. Earlier, the UK introduced a substantial £650 million Life Sciences growth initiative, designed to bolster the government's endeavours in economic expansion.
Several of the funded projects are dedicated to pioneering technologies aimed at enhancing the efficiency and speed of vaccine production. For instance, the financial support granted to the life science company, BioToolomics, will be utilised to optimise the manufacturing process of mRNA medicines and vaccines, resulting in enhanced quality and minimum wastage. This effort seeks to simplify and lower the cost of production. Another beneficiary of the funding, Vitarka, a pre-clinical biotech company will channel its resources into advancing the EndoPore delivery technology, designed to release siRNA drugs within cancer cells. Additional projects set to receive funding are concentrating on the implementation of automation and digitalisation. Another company, Autolomous, for instance, is striving to revolutionise cell and gene therapy manufacturing by integrating automation and digital strategies, ultimately leading to reduced production expenses.
Mark Talford, Deputy Challenge Director, Medicines Manufacturing at Innovate UK, said in the agency’s official press release, ‘‘This support for collaboration across the UK medicines manufacturing landscape to develop innovative nucleic acid medicines will drive forward digitalisation and automation technology’’.
As this substantial investment takes root, the potential to reshape the landscape of medicines manufacturing becomes increasingly tangible, promising a future where innovative solutions pave the way for more efficient, affordable and accessible healthcare on a global scale.